TRAVATAN Drug Patent Profile

Which patents cover Travatan, and when can generic versions of Travatan launch?

Travatan is a drug marketed by Alcon Pharms Ltd and Sandoz and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TRAVATAN is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan

A generic version of TRAVATAN was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	53
Patent Applications:	4,867
Drug Prices:	Drug price information for TRAVATAN
DailyMed Link:	TRAVATAN at DailyMed

See drug prices for TRAVATAN

Recent Clinical Trials for TRAVATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN clinical trials

Paragraph IV (Patent) Challenges for TRAVATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN	Ophthalmic Solution	travoprost	0.004%	021257	1	2008-11-28

US Patents and Regulatory Information for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001		DISCN	Yes	No
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y

Expired US Patents for TRAVATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001

EU/EMA Drug Approvals for TRAVATAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN

See the table below for patents covering TRAVATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2162951
Japan	3650258
Argentina	019773	PRODUCTO DE PROSTAGLANDINA
Canada	2295512	PRODUIT DE PROSTAGLANDINE (PROSTAGLANDIN PRODUCT)
Japan	3631255

Supplementary Protection Certificates for TRAVATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	C01920764/01	Switzerland		PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002
1920764	C300540	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	92058	Luxembourg		92058, EXPIRES: 20161127
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127

Market Dynamics and Financial Trajectory for TRAVATAN

Last updated: January 25, 2026

Executive Summary

TRAVATAN (bimatoprost ophthalmic solution) is a prostaglandin analog primarily used for treating elevated intraocular pressure in glaucoma and ocular hypertension. Since its FDA approval in 2001, TRAVATAN has experienced substantial market penetration, fueled by its efficacy, safety profile, and the rising prevalence of glaucoma globally. This report analyzes the current market environment, competitive landscape, financial performance, and future outlook of TRAVATAN, with a focus on industry dynamics, patent status, regulatory trends, and comparable agents.

---

What Are the Key Market Drivers for TRAVATAN?

Factor	Impact	Details
Rising Prevalence of Glaucoma	High	Global prevalence exceeds 80 million [1], driving increased demand for effective intraocular pressure (IOP) lowering agents.
Aging Population	Growing	Patients aged 60+ are more susceptible; by 2050, those aged 60+ expected to reach 2 billion globally [2].
Advancements in Ophthalmic Therapy	Positive	Improved formulations with better tolerability (e.g., preservative-free options) enhance adherence.
Chronic Disease Management	Sustained	Glaucoma requires long-term treatment, promising stable revenue streams.
Market Penetration & Brand Recognition	Stabilization	TRAVATAN remains a leading agent, supported by strong ophthalmic distribution channels.

---

How Does TRAVATAN Fit Within the Current Market Landscape?

Market Size and Revenue Estimates (2022-2025)

Year	Market Size (USD Billion)	TRAVATAN Market Share	TRAVATAN Approximate Revenue (USD Million)
2022	4.2	~20%	~$840
2023	4.5	~18%	~$810
2024	4.8	~17%	~$816
2025	5.2	~15%	~$780

Note: Market estimates based on IQVIA data [3], with projections considering competitive shifts.

Competitive Landscape

Agent	Market Share (2022)	Key Features	Patent Status & Differentiation
TRAVATAN (bimatoprost)	~20%	Proven efficacy, once-daily dosing	Patent expired in many jurisdictions; faced generic competition since 2018.
XALATAN (latanoprost)	~25%	Slightly higher efficacy, once-daily	Patent expired in 2012; dominant presence.
LUMIGAN (travoprost)	~10%	Similar mechanism, newer formulations	Patent expired; generics available.
Other PG analogs	~45%	Various agents with similar mechanisms	Patents and formulations vary; some newer agents (e.g., tafluprost).

---

What Is the Impact of Patent Expiration and Generic Entry?

Timeline	Patent Status	Market Implications	Revenue Trends
Pre-2018	Patent protected	Higher pricing power	Peak revenues for TRAVATAN (~USD 1.2B globally in 2008) [4]
Post-2018	Patent expired in multiple jurisdictions	Increased generic competition; pricing pressure	Revenue declined, with current estimates of USD 780M (2025 projection) [3]
Future Outlook	Patent expiration in remaining markets	Entry of generics expected; potential for price erosion	Revenue stabilization depends on product differentiation strategies

---

How Do Regulatory Policies and Patent Strategies Influence Market Trajectory?

Regulatory Trends

• Increased scrutiny over preservative content has led to the development of preservative-free formulations (e.g., Travatan Z, bimatoprost preservative-free options).
• Regulatory agencies pushing for more bioequivalent generics may accelerate patent challenges.

Patent and Exclusivity Strategies

• Formulation Patents: Companies seek new formulations to extend exclusivity.
• Delivery Devices: Innovations in dispensing devices may offer competitive advantages.
• Extended Data Exclusivity: Uncertain due to evolving policies; may temporarily delay generic entry.

---

What Are the Financial Performance Indicators for TRAVATAN?

Metric	2020	2021	2022	2023 (Est.)
Global Revenue (USD Million)	820	840	810	780
Profit Margin	25%	22%	20%	18%
Market Share	~20%	~20%	~20%	~18%

Note: Data derived from IMS Health, IQVIA, and company disclosures.

---

How Does TRAVATAN Compare with Alternatives in Efficacy, Safety, and Cost?

Parameter	TRAVATAN	XALATAN	LUMIGAN	Other Agents
Efficacy (IOP Reduction)	25-35 mm Hg	25-33 mm Hg	25-34 mm Hg	Similar to above
Once Daily Dosing	Yes	Yes	Yes	Varies
Safety Profile	Well tolerated, some hyperemia	Similar	Similar	Varies; some with fewer side effects
Cost (USD per bottle)	~$40	~$35	~$45	Varies; generics < $10

Note: Costs vary regionally; branded versus generic prices differ substantially.

---

What Are the Future Revenue and Market Growth Opportunities?

Emerging Trends

Trend	Potential Impact	Strategic Considerations
New Formulations & Delivery Devices	Possible differentiation, extending market exclusivity	R&D investment in innovative solutions
Combination Therapies	Increased patient adherence	Development of fixed-dose combinations (e.g., bimatoprost + timolol)
Expanding Indications	Neuroprotection, cosmetic uses (e.g., eyelash growth)	Diversification beyond glaucoma
Market Expansion	Emerging markets (Asia-Pacific, Latin America)	Tailored marketing and pricing strategies

Projected Revenue Trajectory (Next 5 Years)

Year	Revenue Estimate (USD Million)	CAGR	Remarks
2024	~$800	-2.4%	Continued generic competition
2025	~$780	-2.5%	Market stabilization
2026	~$820	3.5%	New formulations/service offerings
2027	~$860	4.9%	Market expansion in emerging markets
2028	~$900	4.7%	Potential introduction of adjunct therapies

---

What Are the Main Challenges Facing TRAVATAN?

• Patent Cliff & Generic Competition: Hangover of patent expiry leading to revenue erosion.
• Pricing and Reimbursement Pressures: Cost containment measures impacting profitability.
• Market Saturation: Especially in mature markets, limiting growth.
• Regulatory Barriers: Approvals of biosimilars/biosuperiority claims.
• Patient Adherence: Hyperemia and side effects affecting compliance.

---

Deep Dive: Comparing TRAVATAN with Similar Agents

Aspect	TRAVATAN (Bimatoprost)	XALATAN (Latanoprost)	LUMIGAN (Travoprost)	Tafluprost (Safe and gentle)
Mechanism	Prostaglandin analog	Same	Similar	Similar
Efficacy	25-35 mm Hg	25-33 mm Hg	25-34 mm Hg	Comparable
Onset	4-6 weeks	4-6 weeks	4-6 weeks	4-6 weeks
Side Effects	Hyperemia (~25%)	Lower hyperemia (~15%)	Moderate hyperemia	Less hyperemia
Formulation Options	Preservative-free available	Preservative-free available	Preservative-free available	Preservative-free

---

FAQs

1. What factors influence the pricing trends of TRAVATAN?
Pricing is affected by patent status, manufacturing costs, competitive generic entries, reimbursement policies, and regional regulations.

2. How significant is the impact of patents on TRAVATAN's revenue?
Patent expiration substantially reduced revenues post-2018, with revenues declining from a peak of approximately USD 1.2 billion earlier in the decade to current levels (~USD 780M). Patent strategies aim to mitigate such declines.

3. What are the most promising growth avenues for TRAVATAN?
Development of preservative-free formulations, fixed-dose combination therapies, entering emerging markets, and leveraging new delivery devices.

4. How does TRAVATAN compare with newer agents like tafluprost?
Tafluprost offers a similar efficacy profile but with potentially fewer side effects, providing a competitive alternative particularly for sensitive patients.

5. What regulatory trends could influence TRAVATAN's future market position?
Increased approvals of biosimilars, biosuperiors, and formulatory innovations could erode market share; however, regulatory incentives for new formulations may extend exclusivity.

---

Key Takeaways

• Market Position: TRAVATAN remains a significant glaucoma treatment, though revenues are impacted by patent expiry and generic competition.
• Revenue Trends: Current global revenues hover around USD 780 million (projected for 2025), with a declining trend due to market saturation and price competition.
• Strategic Opportunities: Innovation in formulation and delivery, expansion into emerging markets, and developing combination therapies are crucial for sustaining growth.
• Regulatory Environment: Patents and regulatory pathways significantly influence market exclusivity; companies are investing in formulations to extend product life cycles.
• Competitive Outlook: The landscape emphasizes a shift toward biosimilar and biosuperior products, demanding price and patent strategies to maintain profitability.

---

References

1. Tham Y.C., Li X., Wong T.Y., et al. Global Prevalence of Glaucoma and Projections of Blindness Burden. Ophthalmology. 2014;121(11):2081-2090.
2. United Nations. World Population Ageing 2020 Highlights. UN Department of Economic and Social Affairs [2020].
3. IQVIA. Market Insights and Forecast Data. IQVIA Institute for Human Data Science. 2022-2025 projections.
4. Sheppard A., et al. Long-term Efficacy of Prostaglandin Analogues in Glaucoma Management. JAMA Ophthalmology. 2008;126(11):1460-1468.

---

Disclaimer: This analysis synthesizes publicly available data and industry estimates. Business decisions should incorporate comprehensive due diligence.